Immunoterapia topica del carcinoma vescicale con KLH (keyhole limpet hemocyanin): studio controllato di fase 2

Topical immunotherapy, and more precisely BCG, has made considerable steps forward in the topical treatment of superficial bladder cancer. It is therefore important to develop new immunomodulators to work alongside or replace BCG. In this sense, KLH appears promising. The result of a controlled study on patients with carcinoma in-situ is reported. KLH appears active and non-toxic.